share_log

Yunnan Baiyao GroupLtd (SZSE:000538) Shareholders Have Endured a 36% Loss From Investing in the Stock Three Years Ago

Yunnan Baiyao GroupLtd (SZSE:000538) Shareholders Have Endured a 36% Loss From Investing in the Stock Three Years Ago

三年前,雲南白藥集團有限公司(深圳證券交易所代碼:000538)股東因投資該股而遭受了36%的虧損
Simply Wall St ·  04/02 20:23

As an investor its worth striving to ensure your overall portfolio beats the market average. But if you try your hand at stock picking, your risk returning less than the market. We regret to report that long term Yunnan Baiyao Group Co.,Ltd (SZSE:000538) shareholders have had that experience, with the share price dropping 41% in three years, versus a market decline of about 15%.

作爲投資者,值得努力確保您的整體投資組合超過市場平均水平。但是,如果你嘗試選股,你的風險回報低於市場。我們很遺憾地報告,從長遠來看,雲南白藥集團有限公司, Ltd(深圳證券交易所代碼:000538)的股東也有過這樣的經歷,股價在三年內下跌了41%,而市場跌幅約爲15%。

It's worthwhile assessing if the company's economics have been moving in lockstep with these underwhelming shareholder returns, or if there is some disparity between the two. So let's do just that.

值得評估的是,該公司的經濟狀況是否與這些令人難以置信的股東回報步調一致,或者兩者之間是否存在一些差距。所以我們就這麼做吧。

To quote Buffett, 'Ships will sail around the world but the Flat Earth Society will flourish. There will continue to be wide discrepancies between price and value in the marketplace...' One imperfect but simple way to consider how the market perception of a company has shifted is to compare the change in the earnings per share (EPS) with the share price movement.

引用巴菲特的話說:“船隻將在世界各地航行,但Flat Earth Society將蓬勃發展。市場上的價格和價值之間將繼續存在巨大差異...”考慮市場對公司的看法發生了怎樣的變化的一種不完美但簡單的方法是將每股收益(EPS)的變化與股價走勢進行比較。

During the three years that the share price fell, Yunnan Baiyao GroupLtd's earnings per share (EPS) dropped by 9.4% each year. The share price decline of 16% is actually steeper than the EPS slippage. So it seems the market was too confident about the business, in the past.

在股價下跌的三年中,雲南白藥集團有限公司的每股收益(EPS)每年下降9.4%。16%的股價下跌實際上比每股收益的下滑幅度更大。因此,過去市場似乎對該業務過於自信。

The image below shows how EPS has tracked over time (if you click on the image you can see greater detail).

下圖顯示了 EPS 在一段時間內的跟蹤情況(如果你點擊圖片,你可以看到更多細節)。

earnings-per-share-growth
SZSE:000538 Earnings Per Share Growth April 3rd 2024
SZSE: 000538 每股收益增長 2024 年 4 月 3 日

We know that Yunnan Baiyao GroupLtd has improved its bottom line lately, but is it going to grow revenue? This free report showing analyst revenue forecasts should help you figure out if the EPS growth can be sustained.

我們知道雲南白藥集團有限公司最近提高了利潤,但它會增加收入嗎?這份顯示分析師收入預測的免費報告應幫助您弄清楚每股收益的增長是否可以持續。

What About Dividends?

分紅呢?

It is important to consider the total shareholder return, as well as the share price return, for any given stock. The TSR incorporates the value of any spin-offs or discounted capital raisings, along with any dividends, based on the assumption that the dividends are reinvested. It's fair to say that the TSR gives a more complete picture for stocks that pay a dividend. In the case of Yunnan Baiyao GroupLtd, it has a TSR of -36% for the last 3 years. That exceeds its share price return that we previously mentioned. The dividends paid by the company have thusly boosted the total shareholder return.

重要的是要考慮任何給定股票的股東總回報率和股價回報率。基於股息再投資的假設,股東總回報率納入了任何分拆或貼現資本籌集的價值以及任何股息。可以公平地說,股東總回報率爲支付股息的股票提供了更完整的畫面。以雲南白藥集團有限公司爲例,在過去三年中,其股東回報率爲-36%。這超過了我們之前提到的其股價回報率。因此,該公司支付的股息提高了 股東回報。

A Different Perspective

不同的視角

While it's certainly disappointing to see that Yunnan Baiyao GroupLtd shares lost 7.3% throughout the year, that wasn't as bad as the market loss of 14%. Unfortunately, last year's performance may indicate unresolved challenges, given that it's worse than the annualised loss of 2% over the last half decade. While some investors do well specializing in buying companies that are struggling (but nonetheless undervalued), don't forget that Buffett said that 'turnarounds seldom turn'. It's always interesting to track share price performance over the longer term. But to understand Yunnan Baiyao GroupLtd better, we need to consider many other factors. To that end, you should be aware of the 1 warning sign we've spotted with Yunnan Baiyao GroupLtd .

儘管看到雲南白藥集團股份有限公司的股價全年下跌7.3%肯定令人失望,但這還沒有市場14%的跌幅那麼糟糕。不幸的是,去年的表現可能預示着尚未解決的挑戰,因爲它比過去五年中2%的年化虧損還要糟糕。儘管一些投資者在專門收購陷入困境(但仍被低估)的公司方面表現良好,但不要忘記巴菲特說過 “轉機很少會轉機”。長期跟蹤股價表現總是很有意思的。但是,要更好地了解雲南白藥集團有限公司,我們需要考慮許多其他因素。爲此,你應該注意我們在雲南白藥集團有限公司發現的1個警告標誌。

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of companies we expect will grow earnings.

當然,通過尋找其他地方,你可能會找到一筆不錯的投資。因此,請看一下我們預計收益將增加的這份免費公司名單。

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Chinese exchanges.

請注意,本文引用的市場回報反映了目前在中國交易所交易的股票的市場加權平均回報。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論